How GlaxoSmithKline’s Revenues Are Trending in Fiscal 2019 Market Realist
The launch of Mylan’s Wixela Inhub, the generic version of Advair, was a key factor driving down GlaxoSmithKline’s Established Pharmaceuticals revenues.
How GlaxoSmithKline’s Revenues Are Trending in Fiscal 2019 Market Realist
The launch of Mylan’s Wixela Inhub, the generic version of Advair, was a key factor driving down GlaxoSmithKline’s Established Pharmaceuticals revenues.